NCT06580223View on ClinicalTrials.gov

Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

530

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

September 1, 2027

Study Completion Date

September 1, 2027

Conditions
Multiple MyelomaVenous Thromboembolism
Interventions
DRUG

Aspirin 100mg

Aspirin, enteric coating of tablets, oral administration

DRUG

Rivaroxaban 10mg

Rivaroxaban, tablets, oral administration.

Trial Locations (1)

430022

Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER